ALK 阳性转移性非小细胞肺癌（NSCLC）患者在严重的药物诱发精神病后成功重试洛拉替尼：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-07-01 DOI:10.1016/j.jtocrr.2024.100689

{"title":"ALK 阳性转移性非小细胞肺癌（NSCLC）患者在严重的药物诱发精神病后成功重试洛拉替尼：病例报告","authors":"","doi":"10.1016/j.jtocrr.2024.100689","DOIUrl":null,"url":null,"abstract":"<div><p>Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 7","pages":"Article 100689"},"PeriodicalIF":3.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000596/pdfft?md5=258aef7abde42af0bb09cd23862cb12a&pid=1-s2.0-S2666364324000596-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report\",\"authors\":\"\",\"doi\":\"10.1016/j.jtocrr.2024.100689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 7\",\"pages\":\"Article 100689\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000596/pdfft?md5=258aef7abde42af0bb09cd23862cb12a&pid=1-s2.0-S2666364324000596-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000596\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

据报道，在服用中枢神经系统活性 ALK 强效抑制剂洛拉替尼（lorlatinib）的患者中，神经认知不良事件（NAEs）的发生率高达 60%。表现可能包括精神、情绪、言语和认知症状。目前的指南建议，在出现IV级非神经系统毒性反应时，应永久停用lorlatinib。在此，我们报告了一例ALK阳性NSCLC患者在恢复IV级精神病后成功重新挑战剂量降低后的lorlatinib的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks